ARTICLE | Company News
Protherics sells CAMD to Tularik
July 12, 2001 7:00 AM UTC
Protherics (LSE:PTI) sold its Computer-Aided Molecular Design (CAMD) operations to drug discovery play Tularik (TLRK) for 400,000 TLRK shares worth $9.4 million. The CAMD technology includes PTI's Pro...